Sana Biotechnology is a biotechnology company, focusing on utilizing engineered cells as medicines. Co. is developing ex vivo and in vivo cell engineering platforms for treatment across therapeutic areas including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders, among others. Co.'s ex vivo cell engineering pipeline includes its allogeneic T cell program that target CD19 to treat patients with refractory lymphoma. Co.'s in vivo cell engineering pipeline includes its CAR T cell fusosome product candidates (SG242, SG295) target CD19+ cancer cells, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The SANA average annual return since 2021 is shown above.
The Average Annual Return on the SANA average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SANA average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SANA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|